

Friday, April 20th, 2018

18.45-20.00 **Session 8: Upper GI Tumors**

Moderators: **N. Kentepozidis**, A. Karampeazis

- 18.45-19.05 ▶ Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
- ▶ Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

M. Paraskeva

